Please use this identifier to cite or link to this item:
Title: Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study
Author: Hutchings, Martin
Radford, John
Ansell, Stephen M.
Illés, Árpád
Sureda, Anna
Connors, Joseph M.
Sýkorová, Alice
Shibayama, Hirohiko
Abramson, Jeremy S.
Chua, Neil S.
Friedberg, Jonathan W.
Koren, Jan
Steward LaCasce, Ann
Molina, Lysiane
Engley, Gerald
Fenton, Keenan
Jolin, Hina
Liu, Rachel
Gautam, Ashish
Gallamini, Andrea
Keywords: Malaltia de Hodgkin
Assaigs clínics
Pronòstic mèdic
Hodgkin's disease
Clinical trials
Issue Date: 18-Jan-2021
Publisher: John Wiley & Sons
Abstract: Approximately one‐third of patients diagnosed with Hodgkin lymphoma presenting with Stage IV disease do not survive past 5 years. We present updated efficacy and safety analyses in high‐risk patient subgroups, defined by Stage IV disease or International Prognostic Score (IPS) of 4-7, enrolled in the ECHELON‐1 study that compared brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as first‐line therapy after a median follow‐up of 37.1 months. Among patients treated with A + AVD (n = 664) or ABVD (n = 670), 64% had Stage IV disease and 26% had an IPS of 4-7. Patients with Stage IV disease treated with A + AVD showed consistent improvements in PFS at 3 years as assessed by investigator (hazard ratio [HR], 0.723; 95% confidence interval [CI], 0.537-0.973; p = 0.032). Similar improvements were seen in the subgroup of patients with IPS of 4-7 (HR, 0.588; 95% CI, 0.386-0.894; p = 0.012). The most common adverse events (AEs) in A + AVD‐treated versus ABVD‐treated patients with Stage IV disease were peripheral neuropathy (67% vs. 40%) and neutropenia (71% vs. 55%); in patients with IPS of 4-7, the most common AEs were peripheral neuropathy (69% vs. 45%), neutropenia (66% vs. 55%), and febrile neutropenia (23% vs. 9%), respectively. Patients in high‐risk subgroups did not experience greater AE incidence or severity than patients in the total population. This updated analysis of ECHELON‐1 shows a favorable benefit‐risk balance in high‐risk patients.
Note: Reproducció del document publicat a:
It is part of: Hematological Oncology, 2021, Vol.39, num.2, p.185-195
Related resource:
ISSN: 0278-0232
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
706956.pdf482.88 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons